Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpriGard is a veterinary antiparasitic topical solution developed and marketed by Aurora Pharmaceutical. Its active ingredient is eprinomectin, a small molecule belonging to the macrocyclic lactone class. EpriGard is primarily indicated for the treatment and control of internal and external parasites in beef and dairy cattle, including gastrointestinal roundworms, lungworms, grubs, lice, mange mites, and horn flies. It is characterized by its high potency and the convenience of a zero-day withdrawal period for both meat and milk in cattle. Although primarily recognized as a bovine product, Aurora Pharmaceutical categorizes it within its poultry product line on its commercial website, suggesting its application or relevance in avian parasite management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EpriGard.